These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 18979164

  • 1. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.
    Avramidis A, Polyzos SA, Moralidis E, Arsos G, Efstathiadou Z, Karakatsanis K, Grollios G, Kita M.
    J Bone Miner Metab; 2008; 26(6):635-41. PubMed ID: 18979164
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
    Reid IR, Maslowski K.
    Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
    [Abstract] [Full Text] [Related]

  • 3. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F.
    Clin Exp Rheumatol; 2007 Jul; 25(3):464-6. PubMed ID: 17631747
    [Abstract] [Full Text] [Related]

  • 4. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 5. Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1.
    Polyzos SA, Anastasilakis AD, Litsas I, Sapranidis M, Efstathiadou Z, Kita M, Arsos G, Moralidis E, Zafeiriadou E, Papatheodorou A, Terpos E.
    J Clin Densitom; 2010 Jan; 13(2):190-6. PubMed ID: 20347367
    [Abstract] [Full Text] [Related]

  • 6. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N.
    Clin Exp Rheumatol; 2007 Jan; 25(2):206-10. PubMed ID: 17543143
    [Abstract] [Full Text] [Related]

  • 7. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L, Peris P, Guañabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Muñoz-Gomez J, Ballesta AM.
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [Abstract] [Full Text] [Related]

  • 8. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 9. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.
    N Engl J Med; 2005 Sep 01; 353(9):898-908. PubMed ID: 16135834
    [Abstract] [Full Text] [Related]

  • 10. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
    Polyzos SA, Anastasilakis AD, Anagnostis P, Kita M, Arsos G, Moralidis E, Papatheodorou A, Terpos E.
    Endokrynol Pol; 2012 Sep 01; 63(4):312-5. PubMed ID: 22933168
    [Abstract] [Full Text] [Related]

  • 11. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
    Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, Miller PD, Fraser WD, Cafoncelli S, Bucci-Rechtweg C, Hosking DJ.
    J Bone Miner Res; 2011 Sep 01; 26(9):2261-70. PubMed ID: 21638319
    [Abstract] [Full Text] [Related]

  • 12. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM, Scott LJ.
    Drugs; 2007 Sep 01; 67(5):793-804. PubMed ID: 17385948
    [Abstract] [Full Text] [Related]

  • 13. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA, Altayar O, BenKhadra K, Qasim Agha OQ, Asi N, Nabhan M, Prokop LJ, Tebben P, Murad MH.
    Osteoporos Int; 2015 Jul 01; 26(7):1875-91. PubMed ID: 26037791
    [Abstract] [Full Text] [Related]

  • 14. Zoledronic acid for Paget's disease of bone.
    Maricic M.
    Drugs Today (Barc); 2007 Dec 01; 43(12):879-85. PubMed ID: 18174973
    [Abstract] [Full Text] [Related]

  • 15. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D.
    Bone; 2006 Feb 01; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of Paget's disease of bone with zoledronic acid].
    Body JJ, Sternon J.
    Rev Med Brux; 2005 Feb 01; 26(6):513-7. PubMed ID: 16454155
    [Abstract] [Full Text] [Related]

  • 17. [Effect of a single dose of zoledronic acid in a case of Paget bone disease].
    Saban M, Fidalgo S, Díaz CA, Lutfi RJ.
    Medicina (B Aires); 2010 Feb 01; 70(5):445-8. PubMed ID: 20920964
    [Abstract] [Full Text] [Related]

  • 18. The use of zoledronic acid for Paget's disease of bone.
    Maricic M.
    Curr Osteoporos Rep; 2006 Mar 01; 4(1):40-4. PubMed ID: 16527007
    [Abstract] [Full Text] [Related]

  • 19. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
    Polyzos SA, Anastasilakis AD, Litsas I, Efstathiadou Z, Kita M, Arsos G, Moralidis E, Papatheodorou A, Terpos E.
    J Bone Miner Metab; 2010 Nov 01; 28(6):706-12. PubMed ID: 20533067
    [Abstract] [Full Text] [Related]

  • 20.
    Phillips J, Subedi D, Lewis SC, Keerie C, Ralston SH.
    ; 2024 06 01. PubMed ID: 38950131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.